港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

軒竹生物-B

43.000

-6.840-13.72%

成交量：160.74萬

成交額：7,227.68萬

市值：222.74億

市盈率：-34.82

高：50.850

開：49.000

低：43.000

收：49.840

52周最高：96.900

52周最低：23.820

股本：5.18億

香港流通股本：1.61億

量比：0.99

換手率：1.00%

股息：- -

股息率：- -

每股收益(LYR):-1.235

淨資產收益率：--

總資產收益率：--

市淨率：23.16

市盈率(LYR):-34.82

市銷率: 612.99

資料載入中...

總覽公司新聞資訊公告

軒竹生物-B一度飆升60%！吡洛西利片一線適應症近日獲批，入通後資金搶跑佈局

老虎资讯综合

軒竹生物－Ｂ(02575)股價下跌8.15%，現價港幣$43.5

阿斯达克财经

入通靴子落地加速創新價值兑現，軒竹生物-B(02575)迎關鍵配置窗口期

軒竹生物-B(02575.HK)擬3月30日舉行董事會會議審批全年業績

軒竹生物-B盤中異動早盤快速下跌5.35%報49.500港元

港股軒竹生物-B尾盤升逾10%

每日经济新闻

港股公告掘金 | 蒙牛乳業預計年度股東應占利潤將約為14億元至 16億元

四環醫藥：本集團旗下非全資附屬公司軒竹生物被調入滬港通與深港通下港股通標的名單。

軒竹生物-B(02575)獲納入港股通股票名單

海思科1類新藥HSK31679擬納入突破性治療品種；FDA授予Sutacimig突破性療法認定；軒竹生物吡洛西利新適應症獲批上市

軒竹生物-B盤中異動早盤快速跳水5.27%

軒竹生物-B（02575）2026年2月股份變動月報：股本維持不變

國產小分子抗癌藥拿下重磅適應症

3月NMPA批准證明文件：2026年能讓Biotech活下去的，只有這兩種打法

國內外藥企攻堅女性健康，近期新藥突破不斷

國內外藥企共同發力，大批新藥、新適應症同日獲批 / 申報！

軒竹生物-B盤中異動早盤大幅跳水5.08%報57.900港元

軒竹生物-B(02575)：軒悦寧®第三個適應症上市申請獲得NMPA批准，用於一線治療HR+/HER2-晚期乳腺癌

軒竹生物-B：宣愈寧比瑞西利片補充新藥申請獲批新適應症

四環醫藥(00460.HK)附屬軒竹生物獲納入恒生綜合指數成份股

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02575/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02575","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"軒竹生物-B","latestPrice":43,"timestamp":1773994127267,"preClose":49.84,"halted":0,"volume":1607407,"delay":0,"changeRate":-0.13723916532905303,"floatShares":160701996,"shares":518000000,"eps":-1.234826,"marketStatus":"已收盤","change":-6.84,"latestTime":"03-20 16:08:47","open":49,"high":50.85,"low":43,"amount":72276809,"amplitude":0.157504,"askPrice":43.1,"askSize":18000,"bidPrice":43,"bidSize":15000,"shortable":0,"etf":0,"ttmEps":-1.178,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774229400000},"marketStatusCode":5,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":49.84,"openAndCloseTimeList":[[1773970200000,1773979200000],[1773982800000,1773993600000]],"volumeRatio":0.99037,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","floatShares":160701996,"roa":"--","roe":"--","lyrEps":-1.234826,"volumeRatio":0.99037,"shares":518000000,"dividePrice":0,"high":50.85,"amplitude":0.157504,"preClose":49.84,"low":43,"week52Low":23.82,"pbRate":"23.16","psRate":"612.99","week52High":96.9,"institutionHeld":0,"latestPrice":43,"committee":-0.090909,"eps":-1.234826,"divideRate":0,"volume":1607407,"delay":0,"ttmEps":-1.178,"open":49,"prevYearClose":70.5,"prevWeekClose":50,"prevMonthClose":66,"prevQuarterClose":70.5,"fiveDayClose":50,"twentyDayClose":62.15,"sixtyDayClose":70.5,"earningDate":1774800000000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02575\",params:#limit:5,,,undefined,":[{"date":"2026-03-30","symbol":"02575","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02575\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02575\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02575\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02575","date":"2026-03-19","current":-36.655348,"percent":0.913462,"low":-70.039607,"twenty":-56.739151,"median":-54.136108,"eighty":-50.012417,"high":-22.444691,"avg":-52.193456,"sd":7.856957,"marketCap":25814517853},"quantilePoints":[{"date":"2025-10-17","current":-28.93414,"twenty":-27.261252,"median":-24.751919,"eighty":-23.367582,"marketCap":17558430081},{"date":"2025-10-24","current":-50.850969,"twenty":-50.816841,"median":-33.923646,"eighty":-26.424807,"marketCap":30869688284},{"date":"2025-10-31","current":-54.182971,"twenty":-53.663557,"median":-50.808309,"eighty":-28.95487,"marketCap":32941479444},{"date":"2025-11-07","current":-55.367666,"twenty":-55.639174,"median":-53.630543,"eighty":-30.992132,"marketCap":33640708960},{"date":"2025-11-14","current":-54.36116,"twenty":-55.639174,"median":-54.1994,"eighty":-41.200731,"marketCap":33122761170},{"date":"2025-11-21","current":-53.748657,"twenty":-55.319259,"median":-54.136108,"eighty":-50.782713,"marketCap":32734300328},{"date":"2025-11-28","current":-53.384655,"twenty":-55.070724,"median":-54.15954,"eighty":-50.923112,"marketCap":32630710770},{"date":"2025-12-05","current":-54.773392,"twenty":-55.070724,"median":-54.21583,"eighty":-51.627953,"marketCap":33537119402},{"date":"2025-12-12","current":-70.039607,"twenty":-55.665823,"median":-54.261136,"eighty":-53.311356,"marketCap":42963769180},{"date":"2025-12-19","current":-60.019152,"twenty":-56.570931,"median":-54.488669,"eighty":-53.433833,"marketCap":36903780037},{"date":"2025-12-24","current":-59.160975,"twenty":-59.157371,"median":-54.549256,"eighty":-53.581365,"marketCap":36489421805},{"date":"2026-01-02","current":-54.537602,"twenty":-59.158272,"median":-54.690337,"eighty":-53.655303,"marketCap":33770195908},{"date":"2026-01-09","current":-52.983682,"twenty":-59.049917,"median":-54.49123,"eighty":-52.274882,"marketCap":32889684665},{"date":"2026-01-16","current":-58.758617,"twenty":-58.846722,"median":-54.572443,"eighty":-53.169291,"marketCap":36593011363},{"date":"2026-01-23","current":-52.071916,"twenty":-58.705513,"median":-54.4959,"eighty":-52.506318,"marketCap":32397634264},{"date":"2026-01-30","current":-53.326607,"twenty":-57.909955,"median":-54.48995,"eighty":-52.506318,"marketCap":33329940286},{"date":"2026-02-06","current":-57.283358,"twenty":-57.848985,"median":-54.4959,"eighty":-52.506318,"marketCap":35893781847},{"date":"2026-02-13","current":-51.942748,"twenty":-58.578655,"median":-54.516751,"eighty":-52.506318,"marketCap":32734300328},{"date":"2026-02-20","current":-51.153455,"twenty":-58.517685,"median":-54.493565,"eighty":-52.321662,"marketCap":32190455148},{"date":"2026-02-27","current":-53.732962,"twenty":-57.403185,"median":-54.403912,"eighty":-52.138331,"marketCap":34184554140},{"date":"2026-03-06","current":-41.037619,"twenty":-57.295346,"median":-54.261136,"eighty":-51.687579,"marketCap":25897389500},{"date":"2026-03-13","current":-40.849477,"twenty":-57.283358,"median":-54.21583,"eighty":-50.904735,"marketCap":25897389500},{"date":"2026-03-19","current":-40.873529,"twenty":-56.739151,"median":-54.136108,"eighty":-50.012417,"marketCap":25814517853}],"updateTime":1773991586286},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02575\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1130891814","title":"軒竹生物-B一度飆升60%！吡洛西利片一線適應症近日獲批，入通後資金搶跑佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=1130891814","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130891814?lang=zh_tw&edition=fundamental","pubTime":"2026-03-19 10:24","pubTimestamp":1773887083,"startTime":"0","endTime":"0","summary":"3月19日，轩竹生物-B一度飙升60%！轩竹股价在3月9日大幅收涨8.30%，当日股票成交额达到4838.75万港元，较年内日均成交额2244万港元，大幅上涨约116%，入通次日公司股票单日成交额继续上涨至6195.59万港元，显示出港股通资金对轩竹生物的“抢跑布局”。实际上，轩竹生物在二级市场交投活跃度快速回升并获资金抢跑布局，主要得益于市场投资者对公司明确的“创新-商业化”投资逻辑的认可。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8f3c7b18acd8da97ebbf23072ff5b0a2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"gpt_icon":1},{"id":"2620940281","title":"軒竹生物－Ｂ(02575)股價下跌8.15%，現價港幣$43.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2620940281","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620940281?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 13:10","pubTimestamp":1773810600,"startTime":"0","endTime":"0","summary":"[下跌股]轩竹生物－Ｂ(02575) 股价在下午01:10比前收市价下跌8.15%，现股价为港币$43.5。至目前为止，今日最高价为$47.4，而最低价为$43.5。总成交量为36.538万股，总成交金额为港币$1.661千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603181440/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603181440/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02575","BK1191"],"gpt_icon":0},{"id":"2620137274","title":"入通靴子落地加速創新價值兑現，軒竹生物-B(02575)迎關鍵配置窗口期","url":"https://stock-news.laohu8.com/highlight/detail?id=2620137274","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620137274?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 08:26","pubTimestamp":1773707180,"startTime":"0","endTime":"0","summary":"近日，事关创新药的政策利好不断。这对于在二级市场顺利“入通”、核心创新品种一线适应症获批的轩竹生物-B而言，无疑是极大利好。“入通”靴子落地，资金抢跑布局拉长时间线来看，2025年全年，港股通日均成交额为1211亿港元，占港股整体日均成交额的比重达到26.2%。轩悦宁强势挺进乳腺癌一线治疗，引发了业界和市场广泛关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02575"],"gpt_icon":0},{"id":"2619468322","title":"軒竹生物-B(02575.HK)擬3月30日舉行董事會會議審批全年業績","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468322","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468322?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 20:17","pubTimestamp":1773663424,"startTime":"0","endTime":"0","summary":"格隆汇3月16日丨轩竹生物-B(02575.HK)宣布，董事会会议将于2026年3月30日(星期一)举行，藉以(其中包括)考虑及批准集团截至2025年12月31日止年度之全年业绩及其刊发，并考虑建议派发末期股息(如有)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260316/32072306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02575","BK1191"],"gpt_icon":0},{"id":"2618905006","title":"軒竹生物-B盤中異動 早盤快速下跌5.35%報49.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618905006","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618905006?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 10:31","pubTimestamp":1773282702,"startTime":"0","endTime":"0","summary":"2026年03月12日早盘10时31分，轩竹生物-B股票出现异动，股价快速下挫5.35%。截至发稿，该股报49.500港元/股，成交量18.7万股，换手率0.12%，振幅5.93%。资金方面，该股资金流入540.012万港元，流出361.313万港元。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。轩竹生物-B股票所在的生物技术行业中，整体跌幅为1.16%。轩竹生物-B公司简介：轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031210314295499806&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031210314295499806&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02575"],"gpt_icon":0},{"id":"2618643080","title":"港股軒竹生物-B尾盤升逾10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618643080","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618643080?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 15:52","pubTimestamp":1773042721,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月9日，轩竹生物-B(02575.HK)尾盘涨超10%，截至发稿涨10.3%，报55.15港元，成交额4197.63万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603093666060581.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666060581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02575","BK4585","BK1191","BK4588","VXUS"],"gpt_icon":0},{"id":"2618369053","title":"港股公告掘金 | 蒙牛乳業預計年度股東應占利潤將約為14億元至 16億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618369053","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618369053?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 09:03","pubTimestamp":1773018197,"startTime":"0","endTime":"0","summary":"重大事项：恒瑞医药(01276)：阿得贝利单抗注射液获得药物临床试验批准通知书安井食品(02648)拟向河南子公司增资1.2亿元轩竹生物-B(02575)获纳入港股通股票名单派格生物医药-B(02565)：派格生物新一代GLP-1(CR059)首次人体试验取得一个月临床观察结果长风药业(02652)获纳入沪港通及深港通的港股通标的证券名单滨海投资(02886)获提供不超过4500万美元及1.73亿","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0032834883.USD","IE0009570106.USD","LU0128522157.USD","LU0211977185.USD","LU0359201612.USD","LU0287142896.SGD","IE0008368742.USD","HK0000306701.USD","BK1521","LU0348788117.USD","LU1769817179.HKD","02319","LU0672654166.SGD","BK1553","LU0072462343.USD","LU0106959298.USD","LU0029875118.USD","BK1191","IE00B031HY20.USD","LU0259732245.USD","BK1237","LU0650527681.SGD","LU1115378108.SGD","LU2045819591.USD","LU0359201885.HKD","LU0588546209.SGD","LU1769817096.USD","LU0737861699.HKD","HK0000320264.USD","LU1048588211.SGD","LU1224709979.USD","LU2125910500.SGD","LU0307460666.USD","LU0370786039.SGD","LU0651946864.USD","IE00B0169L03.USD","02652","IE00B97KM107.HKD","02575","LU0823426308.USD","LU0594300419.USD","IE00B29SXG58.USD","VT","IE00B031J352.USD","LU0315179316.USD","SG9999002828.SGD","BK1597","LU0163747925.USD","VXUS","LU0251143458.SGD"],"gpt_icon":0},{"id":"2618697300","title":"四環醫藥：本集團旗下非全資附屬公司軒竹生物被調入滬港通與深港通下港股通標的名單。","url":"https://stock-news.laohu8.com/highlight/detail?id=2618697300","media":"新浪财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618697300?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 07:38","pubTimestamp":1773013120,"startTime":"0","endTime":"0","summary":"来源：滚动播报四环医药：本集团旗下非全资附属公司轩竹生物被调入沪港通与深港通下港股通标的名单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309074429a4595305&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309074429a4595305&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","02575","BK1600","BK1191","00460","BK1593"],"gpt_icon":0},{"id":"2617066429","title":"軒竹生物-B(02575)獲納入港股通股票名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2617066429","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617066429?lang=zh_tw&edition=fundamental","pubTime":"2026-03-08 18:20","pubTimestamp":1772965216,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B(02575)发布公告，根据上海证券交易所及深圳证券交易所于2026年3月6日分别发布的《关于沪港通下港股通标的调整的通知》、《关于深港通下的港股通标的证券名单调整的公告》，本公司被调入沪港通与深港通下港股通标的名单，自2026年3月9日起正式生效。沪港通及深港通是香港与中国内地的资本市场投资者之间的股票交易与投资的渠道。董事会认为，本公司被调入沪港通与深港通下港股通标的名单，将有助于扩大本公司的股东群体并提升本公司股份的交易流动性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VT","BK4588","VXUS","BK1191","02575","BK4585"],"gpt_icon":0},{"id":"2617870466","title":"海思科1類新藥HSK31679擬納入突破性治療品種；FDA授予Sutacimig突破性療法認定；軒竹生物吡洛西利新適應症獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2617870466","media":"药财社","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617870466?lang=zh_tw&edition=fundamental","pubTime":"2026-03-06 18:59","pubTimestamp":1772794763,"startTime":"0","endTime":"0","summary":"此次拟纳入突破性治疗程序，有望加速该药物的研发进程与上市审批。2FDA授予Sutacimig突破性疗法认定Hemab Therapeutics今日宣布，美国食品药品监督管理局已授予其在研创新药物Sutacimig突破性疗法认定，旨在预防Glanzmann血小板无力症患者的出血发作。此前，Sutacimig已先后获得FDA授予的快速通道资格与孤儿药资格。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030619064095436413&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030619064095436413&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02575"],"gpt_icon":0},{"id":"2617687075","title":"軒竹生物-B盤中異動 早盤快速跳水5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617687075","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617687075?lang=zh_tw&edition=fundamental","pubTime":"2026-03-06 11:09","pubTimestamp":1772766558,"startTime":"0","endTime":"0","summary":"2026年03月06日早盘11时09分，轩竹生物-B股票出现波动，股价快速跳水5.27%。截至发稿，该股报50.300港元/股，成交量20.65万股，换手率0.13%，振幅6.21%。轩竹生物-B股票所在的生物技术行业中，整体涨幅为2.61%。其相关个股中，药捷安康-B、宜明昂科-B、百奥赛图-B涨幅较大，振幅较大的相关个股有药捷安康-B、百奥赛图-B、映恩生物-B，振幅分别为25.74%、12.13%、11.61%。轩竹生物-B公司简介：轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030611091897a84bac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030611091897a84bac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575","BK1191"],"gpt_icon":0},{"id":"1111409352","title":"軒竹生物-B（02575）2026年2月股份變動月報：股本維持不變","url":"https://stock-news.laohu8.com/highlight/detail?id=1111409352","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111409352?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 16:46","pubTimestamp":1772700417,"startTime":"0","endTime":"0","summary":"轩竹生物科技股份有限公司于2026年3月5日披露2026年2月股份变动月报。本次月报显示，截至2026年2月28日，公司股本结构保持稳定，未发生新发行、回购或注销等变动。轩竹生物科技股份有限公司目前注册股本合计为517,947,790股。截至月末，轩竹生物科技股份有限公司整体股本水平维持不变。公司表示将继续严格遵守香港联交所《上市规则》及其他相关法律法规的要求，按时披露后续股份变动信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7babad1b4c042890cc8c6c387e110b44","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":0},{"id":"2617597371","title":"國產小分子抗癌藥拿下重磅適應症","url":"https://stock-news.laohu8.com/highlight/detail?id=2617597371","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617597371?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 10:16","pubTimestamp":1772676960,"startTime":"0","endTime":"0","summary":"近日，轩竹生物的吡洛西利片获NMPA批准新增适应症，联合芳香化酶抑制剂用于HR+/HER2-晚期乳腺癌初始内分泌治疗，成为国内首个且唯一覆盖该类乳腺癌全疗程的同类药物。吡洛西利是国内首个获批的CDK2/4/6抑制剂，可强效抑制肿瘤细胞增殖，降低血液学毒性，提升治疗耐受性，延缓耐药发生。此前，吡洛西利已获批两项适应症并纳入医保目录，BRIGHT-2和BRIGHT-1研究也分别显示其联合氟维司群及单药治疗具有优异数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305101813a6a47257&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305101813a6a47257&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02575"],"gpt_icon":0},{"id":"2617059737","title":"3月NMPA批准證明文件：2026年能讓Biotech活下去的，只有這兩種打法","url":"https://stock-news.laohu8.com/highlight/detail?id=2617059737","media":"药闻天下","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617059737?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 17:24","pubTimestamp":1772616262,"startTime":"0","endTime":"0","summary":"而手术不仅带来创伤，还可能导致早产、流产等不可逆的生育力损害。希维她的获批，直接重塑了这一临床路径。逆转病程：近60%的患者在首次治疗后6个月，病理结果转为正常或低级别病变，成功免除了手术之苦。深层清毒：治疗12个月时，约60%的基线HPV被成功清除。结合近期行业动态，这款药物在2月末刚刚同日斩获两项新适应症。一个靶点，吃透了整个2型炎症版图。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304182420a6a1c279&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304182420a6a1c279&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575","BK1191"],"gpt_icon":0},{"id":"2617568772","title":"國內外藥企攻堅女性健康，近期新藥突破不斷","url":"https://stock-news.laohu8.com/highlight/detail?id=2617568772","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617568772?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 16:26","pubTimestamp":1772612760,"startTime":"0","endTime":"0","summary":"女性健康领域正成医药创新核心，2026年以来国内外药企新药/新适应症突破不断。亚虹医药核心产品希维她®获批上市，用于治疗子宫颈上皮内瘤变2级，是非手术无创治疗产品，旨在重塑全球治疗标准；轩竹生物自主研发的轩悦宁®第三个适应症获批，成为中国首个覆盖HR+/HER2-晚期乳腺癌全疗程的CDK4/6抑制剂；石药集团注射用紫杉醇白蛋白纳米粒获FDA批准在美国开展临床试验；百利天恒的iza-bren用于局部晚期或转移性三阴乳腺癌III期临床试验期中分析达主要终点，多项适应症被纳入突破性治疗品种名单；默沙东PD-1抑制剂可瑞达®获NMPA批准，用于治疗特定类型子宫内膜癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163918a6a156b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163918a6a156b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2112291526.USD","MRK","LU0070302665.USD","LU1941712264.USD","LU1430594728.SGD","LU2360032135.SGD","LU1066051811.HKD","LU1093756168.USD","LU0320765489.SGD","LU1699723380.USD","LU1934455277.USD","LU0648001328.SGD","LU2089984988.USD","LU1066053197.SGD","LU0234572021.USD","IE0002141913.USD","LU0265550946.USD","IE00BJJMRZ35.SGD","LU1162221912.USD","LU2023250843.SGD","LU1057294990.SGD","BK4550","LU0965509101.SGD","LU2324357040.USD","02575","LU0965509010.AUD","LU0985320562.USD","BK4007","LU1061106388.HKD","SG9999001176.SGD","SG9999001176.USD","LU0211331839.USD","LU1585245621.USD","LU0006306889.USD","BK4585","LU0130517989.USD","SGXZ57979304.SGD","LU0477156953.USD","LU1934455863.HKD","IE000M9KFDE8.USD","SG9999014559.SGD","IE00B2B36J28.USD","LU2468319806.SGD","LU0106261372.USD","SG9999015358.SGD","LU0266013472.USD","LU1116320901.HKD","LU0965508806.USD","LU2125154778.USD","SG9999001440.SGD","IE00BJT1NW94.SGD","LU0203347892.USD","LU2361044865.SGD","LU1093756325.SGD","LU1069347547.HKD","LU0965509283.SGD","IE00B4R5TH58.HKD","LU1989771016.USD","BK4533","LU2461242641.AUD","IE00BLSP4452.SGD","LU1035773651.USD","BK4534","LU2125154935.USD","LU0868494708.USD","LU1989772923.USD","LU0058720904.USD","SG9999014567.USD","LU2361044949.HKD","SG9999013999.USD","LU0942090050.USD","LU0868494617.USD","SG9999002224.SGD","LU1066051225.USD","LU0130102774.USD","LU1983299246.USD","IE00BSNM7G36.USD","LU1023059063.AUD","BK4516","LU0203345920.USD","IE00B1BXHZ80.USD","LU1989772840.SGD","LU1291159041.SGD","LU0238689110.USD","LU0432979614.USD","SG9999002232.USD","01093","SG9999014542.SGD","LU2023250504.SGD","BK4559","LU1037948897.HKD","LU1066051498.USD","LU0320765646.SGD","LU0098860793.USD","LU1929549753.HKD","LU0861579265.USD","LU0122379950.USD","LU1037948541.HKD","IE00BN8TJ469.HKD","LU1571399168.USD","SG9999014575.USD","LU1934455194.USD","IE00BFTCPJ56.SGD","LU0980610538.SGD","LU0265550359.USD","LU0289739699.SGD","IE00BBT3K403.USD","LU2361045086.USD","LU1201861249.SGD","LU2106854487.HKD","LU1116320737.USD","IE0009355771.USD","LU1917777945.USD","LU1941712348.USD","IE00BLSP4239.USD","LU0208291251.USD","SG9999015341.SGD","BK4588","LU1974910355.USD"],"gpt_icon":0},{"id":"2616812581","title":"國內外藥企共同發力，大批新藥、新適應症同日獲批 / 申報！","url":"https://stock-news.laohu8.com/highlight/detail?id=2616812581","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616812581?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 14:33","pubTimestamp":1772606026,"startTime":"0","endTime":"0","summary":"2026年以来，国内已有多款1 类创新药、全球首创产品、新适应症获批上市，同时有多个重磅品种申报上市获受理，覆盖肿瘤、自身免疫、妇科、代谢等核心赛道。如在3月3日，诺和诺德、礼来、亚虹医药等多家药企就相继宣布新药/新适应症在国内申报上市，或获得了《药品注册证书》。截至目前，司美格鲁肽在中国已获批4项适应症。这是吡洛西利继联合氟维司群、单药治疗适应症获批后，在中国获批的第三个适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304143745a449f534&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304143745a449f534&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","BK4132","CDE","LU1223083913.SGD","LU1223082519.USD","AD","BK4017","02575","LU1223082196.USD"],"gpt_icon":0},{"id":"2616583635","title":"軒竹生物-B盤中異動 早盤大幅跳水5.08%報57.900港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616583635","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616583635?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 09:40","pubTimestamp":1772588402,"startTime":"0","endTime":"0","summary":"2026年03月04日早盘09时40分，轩竹生物-B股票出现波动，股价急速跳水5.08%。截至发稿，该股报57.900港元/股，成交量2.7万股，换手率0.02%，振幅4.26%。轩竹生物-B股票所在的生物技术行业中，整体跌幅为0.75%。其相关个股中，和誉-B、晶泰控股、三叶草生物-B涨幅较大，振幅较大的相关个股有帝王国际投资、康诺亚-B、晶泰控股，振幅分别为10.09%、8.15%、6.39%。轩竹生物-B公司简介：轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603040940029542df4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603040940029542df4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02575"],"gpt_icon":0},{"id":"2616317315","title":"軒竹生物-B(02575)：軒悦寧®第三個適應症上市申請獲得NMPA批准，用於一線治療HR+/HER2-晚期乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2616317315","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616317315?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 16:41","pubTimestamp":1772527312,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，本公司自主研发的创新药吡洛西利片联合芳香化酶抑制剂一线治疗HR+/HER2-晚期乳腺癌的新适应症上市申请，已获得中国国家药品监督管理局批准上市。HR+/HER2-乳腺癌是中国最高发的亚型，占病例总数约75%，HR+/HER2 乳腺癌患者中约有30%被诊断为晚期乳腺癌。BRIGHT-3 研究是一项在中国58家中心开展的随机、双盲的III期临床试验，旨在评估吡洛西利联合来曲唑或阿那曲唑一线治疗HR+/HER2-晚期乳腺癌的有效性和安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4203","HR","BK4225","BK1191","02575"],"gpt_icon":0},{"id":"1171371156","title":"軒竹生物-B：宣愈寧比瑞西利片補充新藥申請獲批新適應症","url":"https://stock-news.laohu8.com/highlight/detail?id=1171371156","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171371156?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 16:40","pubTimestamp":1772527222,"startTime":"0","endTime":"0","summary":"轩竹生物-B（股票代码：02575）近日宣布，其核心产品宣愈宁比瑞西利片（Xuanyuening Bireociclib Tablets）的补充新药申请已获得监管机构批准，新增一项重要适应症。此次获批标志着该药物在临床应用范围的进一步拓展，有望为特定患者群体提供新的治疗选择。\n比瑞西利片作为轩竹生物研发的创新药物，此次新适应症的获批将强化其在相关治疗领域的市场竞争力。公司表示，将积极推进该药物的商业化进程，以满足未竟的临床需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"gpt_icon":0},{"id":"2613227810","title":"四環醫藥(00460.HK)附屬軒竹生物獲納入恒生綜合指數成份股","url":"https://stock-news.laohu8.com/highlight/detail?id=2613227810","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613227810?lang=zh_tw&edition=fundamental","pubTime":"2026-02-22 18:37","pubTimestamp":1771756621,"startTime":"0","endTime":"0","summary":"格隆汇2月22日丨四环医药公告，根据恒生指数有限公司于2026年2月13日公布的截至2025年12月31日止期间恒生指数系列季度检讨结果，集团旗下非全资附属公司轩竹生物科技股份有限公司被纳入恒生综合指数成分股，该调整将于2026年3月9日正式生效。　　恒生综合指数作为港股综合性基准指标，全面覆盖在香港联交所主板上市、累计市值位列前95%的上市企业。获纳入恒生综合指数成分股，轩竹生物股份预计将符合沪港通及深港通交易的纳入标准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260222/32021373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02575","BK1191","BK1600","BK1515","00460","BK1593","HSCI"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":126,"code":"91000000","status":"200"}]}}